Cibus to Report Fourth Quarter 2023 Financial Results on March 21, 2024 and Host Conference Call
SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) — Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary […]
SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) — Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary […]
On-track to report topline Phase 3 data from the KOASTAL-1 study with navacaprant in MDD in the second half of […]
MIAMI BEACH, Fla., March 07, 2024 (GLOBE NEWSWIRE) — AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the “Company”), a national provider of […]
Topline data from Phase 2b study of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis (MG) […]
– Additional monotherapy dose-escalation data from ongoing Phase 1/1b clinical trial of WTX-124 expected to be presented in the first […]
– Announced positive topline efficacy and safety data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD […]
CHARLESTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic […]
STAMFORD, Conn., March 07, 2024 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment […]
NEWTOWN, Pa., March 07, 2024 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company […]
NEW YORK and WINNIPEG, Manitoba, March 07, 2024 (GLOBE NEWSWIRE) — Manitoba Harvest, a leader in hemp-based foods and a […]